NCT Number: NCT00219804
Efficacy and Safety of Tetrabenazine in Chorea
The primary objective of this study was to establish the absolute reduction of chorea in participants with Huntington's disease(HD) treated with tetrabenazine or placebo
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- 18 years of age or older
- suffer from manifest HD as confirmed by genetic testing
- Meet chorea and total functional capacity scores on Unified Huntington's Disease Rating Scale
- Meet criteria on Hamilton Depression Rating Scale, Unified Parkinson's Disease Rating Scale dysphagia and dysarthria scale
- Independently ambulatory
Exclusion criteria
- previous treatment with tetrabenazine
- unstable or serious medical or psychiatric illness
- concomitant use identified drugs
- untreated depression
- lack of caregiver
Treatment and study plan
Sponsors and collaborators
Lead sponsor
Prestwick Pharmaceuticals
Industry
Registry information
Official study title
A Randomized, Double-Blind, Placebo-Controlled Study of Tetrabenazine for the Treatment of Huntington's Chorea
Important dates
- First posted
- Sep 22, 2005
- Registry last updated
- Sep 22, 2005
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Real World Effectiveness and Safety of Deutetrabenazine in Adult Chinese Patients With Huntington's Disease (HD) Chorea in China
NCT07601516
Basal Ganglia Diseases, Brain Diseases
Beijing, China
View Trial DetailsChild to Adult Neurodevelopment in Gene Expanded Huntington's Disease
NCT01860339
Basal Ganglia Diseases, Brain Diseases
Sacramento, California, United States
View Trial DetailsA Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)
NCT05107128
Basal Ganglia Diseases, Brain Diseases
Little Rock, Arkansas, United States
View Trial DetailsStudy to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease
NCT03664804
Basal Ganglia Diseases, Brain Diseases
Englewood, Colorado, United States
View Trial Details